Skip to content
Longevity & Aging Series (S3, E7): Amparo Santamaria episode artwork

Nov 17, 2025 38 min

Longevity & Aging Series (S3, E7): Amparo Santamaria

from Aging-US Hosted by Aging Podcast

In this episode of the Longevity & Aging Series, Dr. Amparo Santamaria from the Reproductive Hematology Unit at the IVIRMA Alicante Clinic in Spain joins Dr. Evgeniy Galimov to discuss her #research paper #published in Volume 17, Issue 6 of Aging-US, titled “Enhancing oocyte activation in women with ovarian failure: clinical outcomes of the Stem Cell Regenera study using G-CSF mobilization of peripheral blood stem cells and intraovarian injection of stem cell factor-enriched platelet rich plasma in real-world-practice.” DOI - https://doi.org/10.18632/aging.206274 Corresponding author - Amparo Santamaria - [email protected] Video interview - https://www.youtube.com/watch?v=Zlezd0x_EJQ Longevity & Aging Series - www.aging-us.com/longevity Abstract The study assesses the effectiveness and safety of the Stem Cell Regenera Treatment for oocyte activation in women with ovarian failure, including conditions such as Poor Ovarian Response (POR), Diminished Ovarian Reserve (DOR), and Premature Ovarian Insufficiency (POI). This retrospective observational study was conducted from January 2023 to December 2024 at the IVIRMA Alicante Clinics in Spain. Women diagnosed with ovarian failure participated in the study, which involved mobilizing Hematopoietic Stem Cells from bone marrow into peripheral blood using granulocyte colony- stimulating factor (G-CSF). This was followed by an intraovarian injection of Stem Cell Factor- enriched Platelet Rich Plasma (SCFE-PRP). The primary outcome measures were the rate of oocyte activation, leukocytes and stem cell count, and pregnancy rates. Oocyte activation was defined as an increase in total Antral Follicle Count of three or more follicles after treatment and/or at least a 20% rise in Anti-Müllerian Hormone levels. Safety was assessed based on adverse effects. Pregnancy rates were evaluated for both spontaneous gestation and following in vitro fertilization (IVF) treatment. A total of 145 women participated: the overall activation rate was 68.28%, with 7.07% achieving spontaneous gestation and 14.14% achieving pregnancy following IVF. Mobilization of CD34+ cells was successful in all participants, with an average collection of 32.96 CD34+ cells/μl. No severe adverse effects were observed. The study concluded that the Stem Cell Regenera Treatment is effective and safe for oocyte activation in women with ovarian failure in real-world practice. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206274 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, Stem Cell Regenera, oocyte activation, ovarian regeneration, G-CSF, SCFE-PRP, ovarian failure To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@Aging-US LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc [email protected]

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Longevity & Aging Series (S3, E7): Amparo Santamaria

0:00 38:47

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Aging-US?

This episode is 38 minutes long.

When was this Aging-US episode published?

This episode was published on November 17, 2025.

Can I download this Aging-US episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.